GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Cyclically Adjusted FCF per Share

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Cyclically Adjusted FCF per Share : NT$-0.23 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

TaiGen Biopharmaceuticals Holdings's adjusted free cash flow per share for the three months ended in Mar. 2025 was NT$0.092. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-0.23 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of TaiGen Biopharmaceuticals Holdings was 14.60% per year. The lowest was 14.60% per year. And the median was 14.60% per year.

As of today (2025-05-28), TaiGen Biopharmaceuticals Holdings's current stock price is NT$9.89. TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was NT$-0.23. TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF of today is .


TaiGen Biopharmaceuticals Holdings Cyclically Adjusted FCF per Share Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Cyclically Adjusted FCF per Share Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.45 -0.43 -0.35 -0.28

TaiGen Biopharmaceuticals Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.33 -0.31 -0.28 -0.23

Competitive Comparison of TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Price-to-FCF falls into.


;
;

TaiGen Biopharmaceuticals Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TaiGen Biopharmaceuticals Holdings's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.092/134.9266*134.9266
=0.092

Current CPI (Mar. 2025) = 134.9266.

TaiGen Biopharmaceuticals Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.023 100.684 -0.031
201509 -0.211 100.392 -0.284
201512 -0.329 99.792 -0.445
201603 0.035 100.470 0.047
201606 -0.115 101.688 -0.153
201609 -0.108 101.861 -0.143
201612 -0.042 101.863 -0.056
201703 -0.104 102.862 -0.136
201706 -0.145 103.349 -0.189
201709 -0.086 104.136 -0.111
201712 -0.058 104.011 -0.075
201803 -0.150 105.290 -0.192
201806 -0.090 106.317 -0.114
201809 -0.015 106.507 -0.019
201812 -0.135 105.998 -0.172
201903 -0.102 107.251 -0.128
201906 -0.211 108.070 -0.263
201909 -0.020 108.329 -0.025
201912 -0.140 108.420 -0.174
202003 -0.055 108.902 -0.068
202006 -0.128 108.767 -0.159
202009 -0.078 109.815 -0.096
202012 -0.086 109.897 -0.106
202103 -0.088 111.754 -0.106
202106 0.279 114.631 0.328
202109 0.757 115.734 0.883
202112 -0.117 117.630 -0.134
202203 0.259 121.301 0.288
202206 -0.069 125.017 -0.074
202209 -0.136 125.227 -0.147
202212 -0.126 125.222 -0.136
202303 -0.041 127.348 -0.043
202306 0.013 128.729 0.014
202309 -0.073 129.860 -0.076
202312 0.116 129.419 0.121
202403 -0.307 131.776 -0.314
202406 -0.002 132.554 -0.002
202409 0.030 133.029 0.030
202412 0.034 133.157 0.034
202503 0.092 134.927 0.092

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


TaiGen Biopharmaceuticals Holdings  (ROCO:4157) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


TaiGen Biopharmaceuticals Holdings Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiGen Biopharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines